These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

575 related items for PubMed ID: 27514776

  • 21. [Clinical use of proton pump inhibitors in gastrointestinal diseases].
    Rew JS.
    Korean J Gastroenterol; 2006 Mar; 47(3):181-90. PubMed ID: 16554671
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The Effect of H2 Receptor Antagonist in Acid Inhibition and Its Clinical Efficacy.
    Shim YK, Kim N.
    Korean J Gastroenterol; 2017 Jul 25; 70(1):4-12. PubMed ID: 28728310
    [Abstract] [Full Text] [Related]

  • 24. The rationale of acid suppression in the treatment of acid-related disease.
    Mohamed AH, Hunt RH.
    Aliment Pharmacol Ther; 1994 Jul 25; 8 Suppl 1():3-10. PubMed ID: 7910047
    [Abstract] [Full Text] [Related]

  • 25. Proton pump inhibitors and acid-related diseases.
    Sachs G.
    Pharmacotherapy; 1997 Jul 25; 17(1):22-37. PubMed ID: 9017763
    [Abstract] [Full Text] [Related]

  • 26. Suppression of acid secretion in peptic ulcer disease.
    Feldman M.
    J Clin Gastroenterol; 1995 Jul 25; 20 Suppl 1():S1-6. PubMed ID: 7673607
    [Abstract] [Full Text] [Related]

  • 27. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Mochizuki S, Matsuo K, Isomura Y, Seto M, Suzuki N, Suzuki H, Yamamoto S, Sugimoto T, Omae T, Okamoto M, Watabe H, Togo G, Takano N, Fukui K, Ito Y, Koike K.
    J Dig Dis; 2016 Oct 25; 17(10):670-675. PubMed ID: 27534444
    [Abstract] [Full Text] [Related]

  • 28. Pharmacological Approach to Gastric Acid Suppression: Past, Present, and Future.
    Herszényi L, Bakucz T, Barabás L, Tulassay Z.
    Dig Dis; 2020 Oct 25; 38(2):104-111. PubMed ID: 31846972
    [Abstract] [Full Text] [Related]

  • 29. Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease.
    Ramani A, Merchant A, Cash BD.
    Eur J Clin Pharmacol; 2023 Aug 25; 79(8):1023-1029. PubMed ID: 37344679
    [Abstract] [Full Text] [Related]

  • 30. A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.
    Yu LY, Sun LN, Zhang XH, Li YQ, Yu L, Yuan ZQ, Meng L, Zhang HW, Wang YQ.
    Adv Ther; 2017 May 25; 34(5):1070-1086. PubMed ID: 28429247
    [Abstract] [Full Text] [Related]

  • 31. Drugs for peptic ulcer disease and GERD.
    Treat Guidel Med Lett; 2011 Sep 25; 9(109):55-60; quiz 2 p following 60. PubMed ID: 21860368
    [No Abstract] [Full Text] [Related]

  • 32. Proton pump inhibitors: the beginning of the end or the end of the beginning?
    Scarpignato C, Hunt RH.
    Curr Opin Pharmacol; 2008 Dec 25; 8(6):677-84. PubMed ID: 18840545
    [Abstract] [Full Text] [Related]

  • 33. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease.
    Kim DK, Lee KH, Kim SJ, Kim SJ, Lee SJ, Park CH, Kim BT, Song GS, Moon BS, Ryu SY.
    J Pharmacol Exp Ther; 2019 Jun 25; 369(3):318-327. PubMed ID: 30894456
    [Abstract] [Full Text] [Related]

  • 34. Pharmacology of proton pump inhibitors.
    Shin JM, Sachs G.
    Curr Gastroenterol Rep; 2008 Dec 25; 10(6):528-34. PubMed ID: 19006606
    [Abstract] [Full Text] [Related]

  • 35. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases.
    Robinson M.
    Int J Clin Pract; 2005 Jun 25; 59(6):709-15. PubMed ID: 15924600
    [Abstract] [Full Text] [Related]

  • 36. Acid-related disorders in the elderly.
    Franceschi M, Di Mario F, Leandro G, Maggi S, Pilotto A.
    Best Pract Res Clin Gastroenterol; 2009 Jun 25; 23(6):839-48. PubMed ID: 19942162
    [Abstract] [Full Text] [Related]

  • 37. Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and Helicobacter pylori.
    Antequera CM, Orleck K, Jacob R, Kenneally A, Wright WL.
    Postgrad Med; 2024 Mar 25; 136(2):131-140. PubMed ID: 38385191
    [Abstract] [Full Text] [Related]

  • 38. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases.
    Oshima T, Miwa H.
    J Neurogastroenterol Motil; 2018 Jul 30; 24(3):334-344. PubMed ID: 29739175
    [Abstract] [Full Text] [Related]

  • 39. Vonoprazan: A New Potassium-Competitive Acid Blocker.
    St Onge E, Phillips B.
    J Pharm Technol; 2023 Jun 30; 39(3):139-146. PubMed ID: 37323765
    [Abstract] [Full Text] [Related]

  • 40. [Evidence and uncertainties on the clinical use of proton pump inhibitors].
    de Prados CM.
    Gastroenterol Hepatol; 2010 May 30; 33 Suppl 1():5-10. PubMed ID: 20728783
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.